Parallel Advisors, LLC Arcus Biosciences, Inc. Transaction History

Parallel Advisors, LLC

$4.34 Billion
Q4 2024

A detailed history of Parallel Advisors, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 85,807 shares of RCUS stock, worth $767,114. This represents 0.03% of its overall portfolio holdings.

Number of Shares

85,807

Previous 85,807 -0.0%

Holding current value

$767,114

Previous $1.31 Million 2.59%

% of portfolio

0.03%

Previous 0.03%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$13.69 - $18.01 $205 - $270	-15 Reduced 0.02%	85,807 $1.31 Million
Q2 2024 Aug 08, 2024	BUY	$14.59 - $18.48 $218 - $277	15 Added 0.02%	85,822 $1.31 Million
Q1 2024 May 06, 2024	BUY	$14.83 - $20.18 $1,112 - $1,513	75 Added 0.09%	85,807 $1.62 Million
Q4 2023 Feb 09, 2024	BUY	$13.43 - $19.63 $4,700 - $6,870	350 Added 0.41%	85,732 $1.64 Million
Q1 2023 May 20, 2024	SELL	$15.96 - $23.15 $6,783 - $9,838	-425 Reduced 0.5%	85,382 $1.56 Million
Q1 2023 Apr 25, 2023	BUY	$15.96 - $23.15 $3,591 - $5,208	225 Added 0.26%	85,382 $1.56 Million
Q4 2022 Feb 03, 2023	BUY	$19.7 - $35.71 $5,811 - $10,534	295 Added 0.35%	85,157 $1.76 Million
Q3 2022 Nov 10, 2022	BUY	$23.23 - $30.07 $116 - $150	5 Added 0.01%	84,862 $2.22 Million
Q2 2022 Aug 01, 2022	BUY	$17.23 - $37.73 $499 - $1,094	29 Added 0.03%	84,857 $2.15 Million
Q1 2022 Apr 28, 2022	BUY	$28.92 - $41.83 $723 - $1,045	25 Added 0.03%	84,828 $2.83 Million
Q4 2021 Jan 20, 2022	SELL	$31.38 - $48.47 $5,648 - $8,724	-180 Reduced 0.21%	84,803 $3.43 Million
Q3 2021 Nov 02, 2021	SELL	$26.93 - $37.68 $6,517 - $9,118	-242 Reduced 0.28%	84,983 $2.96 Million
Q3 2020 Oct 27, 2020	SELL	$17.14 - $25.47 $28,366 - $42,152	-1,655 Reduced 1.9%	85,225 $1.46 Million
Q2 2020 Jul 16, 2020	SELL	$13.97 - $36.56 $10,253 - $26,835	-734 Reduced 0.84%	86,880 $2.15 Million
Q1 2020 Apr 27, 2020	BUY	$8.78 - $19.28 $6,664 - $14,633	759 Added 0.87%	87,614 $1.22 Million
Q4 2019 Jan 30, 2020	BUY	$7.33 - $10.79 $5,864 - $8,632	800 Added 0.93%	86,855 $877,000
Q3 2019 Nov 01, 2019	BUY	$6.44 - $10.18 $550,169 - $869,677	85,430 Added 13668.8%	86,055 $783,000
Q2 2019 Aug 05, 2019	BUY	$7.29 - $13.38 $4,556 - $8,362	625 New	625 $5,000

Others Institutions Holding RCUS

# of Institutions

201

Shares Held

51.2M

Call Options Held

288K

Put Options Held

138K

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $645M
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.

Account

Parallel Advisors, LLC Arcus Biosciences, Inc. Transaction History